Literature DB >> 8573294

Lipid formulations of amphotericin B. Less toxicity but at what economic cost?

J Tollemar1, O Ringdén.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8573294     DOI: 10.2165/00002018-199513040-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  57 in total

1.  Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers.

Authors:  S W Sanders; K N Buchi; M S Goddard; J K Lang; K G Tolman
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 2.  Overview of liposomes.

Authors:  G Gregoriadis
Journal:  J Antimicrob Chemother       Date:  1991-10       Impact factor: 5.790

Review 3.  Liposomes as drug delivery system in the treatment of infectious diseases. Potential applications and clinical experience.

Authors:  A Coune
Journal:  Infection       Date:  1988 May-Jun       Impact factor: 3.553

4.  Anaphylactic reactions to liposomal amphotericin.

Authors:  R B Laing; L J Milne; C L Leen; G P Malcolm; A J Steers
Journal:  Lancet       Date:  1994-09-03       Impact factor: 79.321

5.  Amphotericin B-induced nephrogenic diabetes insipidus: resolution with its liposomal counterpart.

Authors:  O P Smith; R Gale; M Hamon; P McWhinney; H G Prentice
Journal:  Bone Marrow Transplant       Date:  1994-01       Impact factor: 5.483

6.  Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS.

Authors:  R J Coker; M Viviani; B G Gazzard; B Du Pont; H D Pohle; S M Murphy; J Atouguia; J L Champalimaud; J R Harris
Journal:  AIDS       Date:  1993-06       Impact factor: 4.177

Review 7.  Overview of the treatment of disseminated fungal infections.

Authors:  R J Hay
Journal:  J Antimicrob Chemother       Date:  1991-10       Impact factor: 5.790

8.  Successful treatment of fungal infections in neutropenic patients with liposomal amphotericin (AmBisome)--a report on 40 cases from a single centre.

Authors:  R Chopra; A Fielding; A H Goldstone
Journal:  Leuk Lymphoma       Date:  1992

9.  Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients.

Authors:  J Tollemar; O Ringdén; S Andersson; B Sundberg; P Ljungman; G Tydén
Journal:  Bone Marrow Transplant       Date:  1993-12       Impact factor: 5.483

10.  Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury.

Authors:  H Shulman; G Striker; H J Deeg; M Kennedy; R Storb; E D Thomas
Journal:  N Engl J Med       Date:  1981-12-03       Impact factor: 91.245

View more
  8 in total

Review 1.  The cost of treating systemic fungal infections.

Authors:  R van Gool
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Economic evaluation of intravenous itraconazole for presumed systemic fungal infections in neutropenic patients in Korea.

Authors:  K Moeremans; L Annemans; Ji-So Ryu; Kang-Won Choe; Wan-Shik Shine
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

Review 3.  Advanced and controlled drug delivery systems in clinical disease management.

Authors:  J R Brouwers
Journal:  Pharm World Sci       Date:  1996-10

Review 4.  Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.

Authors:  A J Coukell; R N Brogden
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

Review 5.  Bone marrow transplantation using unrelated donors for haematological malignancies.

Authors:  O Ringdén
Journal:  Med Oncol       Date:  1997-03       Impact factor: 3.064

6.  Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis.

Authors:  A B Mullen; K C Carter; A J Baillie
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

Review 7.  Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.

Authors:  R N Brogden; K L Goa; A J Coukell
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 8.  Liposomes as nanomedical devices.

Authors:  Giuseppina Bozzuto; Agnese Molinari
Journal:  Int J Nanomedicine       Date:  2015-02-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.